title: Prostanoids as pharmacological targets in COPD and asthma.
abstract: COPD (Chronic Obstructive Pulmonary Disease) and bronchial asthma are two severe lung diseases which represent a major problem of world public health. Leukotrienes and prostanoids play an important role in the pathogenesis of pulmonary diseases. Prostanoids: prostaglandins (PGs) and thromboxane A2 (TXA2), the cyclooxygenase metabolites of arachidonic acid are implicated in the inflammatory cascade that occurs in asthmatic airways. Recently, the roles played by isoprostanes or prostaglandin-like compounds nonenzymatically generated via peroxidation of membrane phospholipids by reactive oxygen species, in particular F2-isoprostanes, in pulmonary pathophysiology have been highlighted. This article aims to provide an overview of the role of prostanoids and isoprostanes in the pathogenesis of COPD and asthma and to discuss the pharmacological strategies developed in prevention and/or treatment of these pathologies.
authors.affiliation: Department of Pharmacy, University of Namur, Rue de Bruxelles 61, B-5000 Namur, Belgium.
authors.forename: Stéphanie
authors.initials: S
authors.lastname: Rolin
authors.forename: Bernard
authors.initials: B
authors.lastname: Masereel
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Dogné
mesh_terms: D000818:Animals; D001249:Asthma / Q000188:drug therapy / Q000378:metabolism*; D016227:Benzoquinones / Q000494:pharmacology / Q000627:therapeutic use; D002227:Carbazoles / Q000494:pharmacology / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D028441:F2-Isoprostanes / Q000378:metabolism; D006538:Heptanoic Acids / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008689:Methacrylates / Q000494:pharmacology / Q000627:therapeutic use; D011448:Prostaglandin Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D015230:Prostaglandin D2 / Q000378:metabolism*; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy / Q000378:metabolism*; D016032:Randomized Controlled Trials as Topic; D011971:Receptors, Immunologic / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011982:Receptors, Prostaglandin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D044244:Receptors, Thromboxane A2, Prostaglandin H2 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use; D013928:Thromboxane A2 / Q000378:metabolism; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D016227:Benzoquinones; D002227:Carbazoles; D004791:Enzyme Inhibitors; D028441:F2-Isoprostanes; D006538:Heptanoic Acids; D008689:Methacrylates; D011448:Prostaglandin Antagonists; D011971:Receptors, Immunologic; D011982:Receptors, Prostaglandin; D044244:Receptors, Thromboxane A2, Prostaglandin H2; D013449:Sulfonamides; C060230:seratrodast; D013928:Thromboxane A2; D013930:Thromboxane-A Synthase; C034364:ozagrel; C063119:ramatroban; D015230:Prostaglandin D2; C036293:prostaglandin D2 receptor